Dr. Ravi Salgia On Eml4-Alk In A Cancer Cell

Dr. Ravi Salgia on EML4-ALK in a Cancer Cell

Targeted Oncology

Dr. Li Discusses the EML4-ALK Fusion Gene

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

Dr. Ravi Salgia on Crizotinib-Resistant Patients

Targeted Oncology

Dr. Kris on the EML4-ALK Translocation

Dr. Salgia on Next-Generation Sequencing in Lung Cancer

2021 ASCO Direct San Francisco | Metastatic Lung Cancer Summary | Dr. Ravi Salgia

Total Health | Oncology

2020 West Oncology Conference - Ravi Salgia, MD | Key Takeaways from the Immunotherapy Discussion

Total Health | Oncology

Ravi Salgia, MD, PhD | What's Exciting About Lung Cancer at 2018 Best of ASCO St. Louis

Total Health | Oncology

Dr. Ravi Salgia Describes Molecular Applications in Advanced Lung Cancer

Targeted Oncology

How do ALK-inhibitors work in ALK-positive lung cancer?

Introduction to ALK inhibitors

LUNGevityFoundation

Best of iMig 2014 - Dr. Ravi Salgia presents "From Chaos to Mitochondrial Functionality"

iMig -The International Mesothelioma Interest Group

GRACEcastUC108_Lung_Dr. Salgia on Targeted Therapies Generalizable

GRACE - Global Resource for Advancing Cancer Education

Alecensa: Targeted Therapy for ALK-Positive Lung Cancer

Medical Centric

ASCO Lung Cancer Update | Ravi Salgia, MD, PhD | 2022 Review and Renew Sedona

Total Health | Oncology

Choosing the best ALK inhibitor for lung cancer

ASCO22 Lung Cancer Key Takeaways | Ravi Salgia, MD, PhD | 2022 Review and Renew Sedona

Total Health | Oncology

GRACEcastUC-059_Lung_Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"

GRACE - Global Resource for Advancing Cancer Education

GRACEcastUC-071_Lung_How Do I Discuss the Side Effects of Targeted Therapies Compared with Chemo?

GRACE - Global Resource for Advancing Cancer Education